Kala Pharmaceuticals Inc (NASDAQ:KALA) – Research analysts at Wedbush upped their FY2018 EPS estimates for shares of Kala Pharmaceuticals in a report issued on Wednesday, November 14th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of ($2.11) per share for the year, up from their previous estimate of ($2.15). Wedbush has a “Buy” rating and a $51.00 price target on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ Q4 2018 earnings at ($0.45) EPS, Q1 2019 earnings at ($0.43) EPS, Q2 2019 earnings at ($0.52) EPS, Q3 2019 earnings at ($0.64) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($2.20) EPS, FY2020 earnings at $0.00 EPS, FY2021 earnings at $3.87 EPS and FY2022 earnings at $9.95 EPS.

KALA has been the topic of several other research reports. HC Wainwright increased their target price on shares of Kala Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, August 24th. Wells Fargo & Co reissued a “buy” rating and issued a $15.00 target price (down previously from $19.00) on shares of Kala Pharmaceuticals in a research note on Thursday, October 4th. BidaskClub raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Finally, Zacks Investment Research raised shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research note on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $22.45.

Shares of KALA opened at $6.10 on Monday. Kala Pharmaceuticals has a twelve month low of $6.01 and a twelve month high of $22.10. The firm has a market capitalization of $223.73 million, a PE ratio of -1.04 and a beta of 0.63. The company has a current ratio of 6.34, a quick ratio of 6.27 and a debt-to-equity ratio of 0.30.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its earnings results on Thursday, November 8th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01).

In other news, Director Gregory Grunberg bought 606,060 shares of Kala Pharmaceuticals stock in a transaction dated Friday, October 5th. The shares were acquired at an average price of $8.25 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Healthcare Fund Lp bought 2,424,242 shares of Kala Pharmaceuticals stock in a transaction dated Wednesday, October 3rd. The stock was purchased at an average cost of $8.25 per share, for a total transaction of $19,999,996.50. The disclosure for this purchase can be found here. Corporate insiders own 35.58% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $140,000. Rhumbline Advisers purchased a new position in Kala Pharmaceuticals in the 2nd quarter worth about $148,000. Paloma Partners Management Co purchased a new position in Kala Pharmaceuticals in the 2nd quarter worth about $152,000. Virtu Financial LLC purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $200,000. Finally, Engineers Gate Manager LP purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $249,000. 49.61% of the stock is currently owned by institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: What is a Swap?

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.